<DOC>
	<DOCNO>NCT02782624</DOCNO>
	<brief_summary>To investigate influence different dosage regimen ( 5 mg twice daily versus 10 mg daily ) steady state pharmacokinetics pharmacodynamics BI 10773 administer orally</brief_summary>
	<brief_title>Relative Bioavailability BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : Healthy male females accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test Age = 18 Age = 50 year BMI = 18.5 = 29.9 kg/m2 ( Body Mass Index ) Signed date write informed consent prior admission study accordance GCP local legislation . Exclusion criterion : Any find medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 6 . History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug within one month le 10 halflives respective drug prior first study drug administration except relevant interaction rule Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( average consumption 20 g/day female 30 g/day male ) Drug abuse Blood donation ( 100 mL within four week prior start study ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor TdP ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) For female subject : Positive pregnancy test , pregnancy plan become pregnant study within 1 month study completion No adequate contraception study 1 month study completion , i.e . follow : implant , injectables , combine oral contraceptive , IUD A record subject screen , exclude , maintain . ( intrauterine device ) , sexual abstinence least 1 month prior enrolment , vasectomised partner ( vasectomy perform least 1 year prior enrolment ) , surgical sterilisation ( include hysterectomy ) . Females , vasectomise partner , sexually abstinent surgically sterile ask use additional barrier method ( e.g . condom , diaphragm spermicide ) Lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>